Artal Group S.A. Vor Biopharma Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$1.8 - $2.85 $2.43 Million - $3.84 Million	-1,347,424 Reduced 57.4%	1,000,000 $2.37 Million
Q4 2023 Feb 09, 2024	SELL	$1.66 - $2.63 $565,381 - $895,754	-340,591 Reduced 12.67%	2,347,424 $5.28 Million
Q2 2023 Aug 11, 2023	SELL	$3.09 - $5.33 $323,801 - $558,530	-104,790 Reduced 3.75%	2,688,015 $8.31 Million
Q1 2023 May 12, 2023	SELL	$4.68 - $6.96 $387,391 - $576,120	-82,776 Reduced 2.88%	2,792,805 $15 Million
Q4 2022 Feb 13, 2023	BUY	$3.77 - $7.43 $8.77 Million - $17.3 Million	2,325,581 Added 422.83%	2,875,581 $19.1 Million
Q1 2021 May 14, 2021	BUY	$30.96 - $54.08 $17 Million - $29.7 Million	550,000 New	550,000 $23.7 Million

41.2M

9.3K

100

Ticker VOR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,056,300
Market Cap $32.7M
Description
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AM...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.